These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16396771)

  • 1. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
    Di Renzo N; Brugiatelli M; Montanini A; Vigliotti ML; Cervetti G; Liberati AM; Luminari S; Spedini P; Giglio G; Federico M
    Leuk Lymphoma; 2006 Mar; 47(3):473-9. PubMed ID: 16396771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
    Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
    Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
    Müller-Beissenhirtz H; Kasper C; Nückel H; Dührsen U
    Ann Hematol; 2005 Nov; 84(12):796-801. PubMed ID: 16041531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
    Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
    Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
    Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
    J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
    Santoro A; Magagnoli M; Spina M; Pinotti G; Siracusano L; Michieli M; Nozza A; Sarina B; Morenghi E; Castagna L; Tirelli U; Balzarotti M
    Haematologica; 2007 Jan; 92(1):35-41. PubMed ID: 17229633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Something old, something new...
    Smith S
    Leuk Lymphoma; 2006 Apr; 47(4):576-7. PubMed ID: 16886269
    [No Abstract]   [Full Text] [Related]  

  • 13. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
    Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
    Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.
    Pasricha SR; Grigg A; Catalano J; Leahy M; Underhill C; Arthur C; D'Rozario J; Lowenthal R; Reed K; Spencer A
    Cancer; 2008 Dec; 113(11):3192-8. PubMed ID: 18932253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
    Cole PD; Schwartz CL; Drachtman RA; de Alarcon PA; Chen L; Trippett TM
    J Clin Oncol; 2009 Mar; 27(9):1456-61. PubMed ID: 19224841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
    Naqi N; Ahmad S; Shah I; Khattak J
    J Coll Physicians Surg Pak; 2013 Jun; 23(6):397-400. PubMed ID: 23763798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience).
    Radman I; Basić N; Labar B; Kovacević J; Aurer I; Bogdanić V; Zupancić-Salek S; Nemet D; Jakić-Razumović J; Mrsić M; Santek F; Grgić-Markulin L; Boban D
    Ann Oncol; 2002 Oct; 13(10):1650-5. PubMed ID: 12377656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
    Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
    Balzarotti M; Brusamolino E; Angelucci E; Carella AM; Vitolo U; Russo E; Congiu A; Gotti M; Massidda S; Botto B; Annechini G; Spina M; Re A; Zilioli VR; Merli F; Salvi F; Stelitano C; Bonfichi M; Rodari M; Murru R; Magagnoli M; Anastasia A; Mazza R; Giordano L; Santoro A
    Leuk Lymphoma; 2016 Oct; 57(10):2375-81. PubMed ID: 26879066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
    Mian M; Farsad M; Pescosta N; Casini M; Cavattoni IM; Deola S; Cortelazzo S
    Ann Hematol; 2013 Jan; 92(1):121-3. PubMed ID: 22820997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.